Table 2.

Effects of EGCG on oral diseases

Study Design	Results/Effects	Ref
In vitro	Inhibition of the planktonic growth and the biofilm formation	[129, 130]
In vitro	Decrease of S. mutans EPS production	[131, 132]
In vitro	Protected keratinocytes against the TNF- -mediated breakdown of barrier integrity	[133, 134]
In vitro	Prevented bacterial adhesion and F. nucleatum-mediated hemolysis	[135, 136]
In vitro	Blocked S. moorei growth and bacterial adherence Declined of the biofilm formation Repression of bacterial-galactosidase activity	[135, 137]
In vitro and In vivo	Inhibition of p-focal adhesion kinase (p-FAK), p-Src, snail-1, and vimentin	[127, 138]
In vitro	Reduced expressions of MMP-2, MMP-9, and uPA in a dose-dependent way	[124, 139]
In vitro and In vivo	Decrease the toxicity of acrolein	[111]
In vitro	Inactivation of oral viruses such as HPV, HSV and other viral proteins	[140]
In vitro	Inhibits the NADPH oxidase translocation and ROS production	[141]
In vitro	Inhibits the growth of P. gingivalis and reduces CH3SH production and mgl gene expression	[112]
In vitro	Decreased the β-galactosidase gene expression	[142]